95 related articles for article (PubMed ID: 3133799)
1. [Changes in concentrations of IgM, IgA and IgM immune globulins after megavolt therapy with the large-field technic in patients with Hodgkin's disease].
Krüsmann W; Slanina J; Boser F; Löhr GW
Strahlenther Onkol; 1988 Jun; 164(6):323-9. PubMed ID: 3133799
[TBL] [Abstract][Full Text] [Related]
2. [Changes in isoagglutinin titers after high-voltage therapy with the large-field technic in Hodgkin's disease patients].
Krüsmann W; Slanina J; Wannenmacher M; Nolte I
Strahlenther Onkol; 1988 Feb; 164(2):79-84. PubMed ID: 3125619
[TBL] [Abstract][Full Text] [Related]
3. [Cellular immune response and concentrations of serum immunoglobulins in patients with Hodgkin's disease (author's transl)].
Stefanits K; Kuhn E; Ambrus M; Csere T
Strahlentherapie; 1979 May; 155(5):335-40. PubMed ID: 442117
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobin levels in patients with Hodgkin's disease.
Dienstbier Z; Koprivová H; Bechynĕ M; Zizkovský V; Foltýnová V; Rezný Z; Jirkovský J
Neoplasma; 1978; 25(6):723-31. PubMed ID: 752117
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of serum innumoglobulin levels in Hodgkin's disease.
Alsabti EA; Shaheen A
Neoplasma; 1979; 26(3):329-33. PubMed ID: 530336
[TBL] [Abstract][Full Text] [Related]
6. Alterations of IgE immunoglobulin concentration in the serum after megavoltage radiotherapy with large-field technique in patients with Hodgkin's disease.
Krüsmann W; Slanina J; Nolte I
Strahlenther Onkol; 1990 Apr; 166(4):265-70. PubMed ID: 2109876
[TBL] [Abstract][Full Text] [Related]
7. Serum immunoglobulin levels in childhood Hodgkin's disease. Effect of splenectomy and long-term follow-up.
Walzer PD; Armstrong D; Weisman P; Tan C
Cancer; 1980 Apr; 45(8):2084-9. PubMed ID: 7370954
[TBL] [Abstract][Full Text] [Related]
8. [IgG, IgA and IgM levels in Hodgkin's disease].
Dziewulska-Bakiniec A; Piskorzyńska M
Wiad Lek; 1981 Apr; 34(8):635-8. PubMed ID: 7303678
[No Abstract] [Full Text] [Related]
9. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
10. [Immunglobulins G, A, M, and E in lymphogranulomatosis (author's transl)].
Steidle C; Fateh-Moghadam A; Lamerz R; Huhn D; Ehrhart H
MMW Munch Med Wochenschr; 1976 Apr; 118(16):503-8. PubMed ID: 818517
[TBL] [Abstract][Full Text] [Related]
11. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
Campbell BA; Voss N; Pickles T; Morris J; Gascoyne RD; Savage KJ; Connors JM
J Clin Oncol; 2008 Nov; 26(32):5170-4. PubMed ID: 18838714
[TBL] [Abstract][Full Text] [Related]
12. Immune reactive proteins in patients irradiated for cervical cancer. One year follow up.
Juranić Z; Vucković-Dekić L; Durbaba M
Neoplasma; 1994; 41(4):225-8. PubMed ID: 7935997
[TBL] [Abstract][Full Text] [Related]
13. What is the optimal treatment volume in Hodgkin's disease patients undergoing high-dose chemotherapy and adjuvant radiation therapy?
Mundt AJ; Connell PP; Mansur DB
Radiat Oncol Investig; 1999; 7(6):353-9. PubMed ID: 10644058
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
15. Hodgkin's disease. Results from a program in radiation therapy.
Micaily B; Brady LW
Am J Clin Oncol; 1984 Apr; 7(2):159-71. PubMed ID: 6422736
[TBL] [Abstract][Full Text] [Related]
16. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
[TBL] [Abstract][Full Text] [Related]
17. [Etiology of pericardial effusion following radiation therapy of Hodgkin's disease].
Kurtz B; Maisch B; Voss AC
Strahlentherapie; 1981 Sep; 157(9):571-5. PubMed ID: 7347436
[TBL] [Abstract][Full Text] [Related]
18. Combined modality therapy in previously untreated patients with advanced Hodgkin's disease: A 24-year follow-up study.
Salloum E; Doria R; Farber LR; Roberts KB; Cooper DL
Cancer J Sci Am; 1995; 1(4):267-73. PubMed ID: 9166487
[TBL] [Abstract][Full Text] [Related]
19. Time-course changes of serum immunoglobulins (IgA, IgG, IgM) after liver transplantation for alcoholic cirrhosis.
González-Quintela A; López-Ben S; Pérez LF; Graña B; Varela M; Tomé S; Varo E
Transpl Immunol; 2003; 11(1):73-7. PubMed ID: 12727478
[TBL] [Abstract][Full Text] [Related]
20. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease.
Donaldson SS; Link MP; Weinstein HJ; Rai SN; Brain S; Billett AL; Hurwitz CA; Krasin M; Kun LE; Marcus KC; Tarbell NJ; Young JA; Hudson MM
J Clin Oncol; 2007 Jan; 25(3):332-7. PubMed ID: 17235049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
